Emilio Flano

Emilio Flano brings to Ensoma 25 years of experience as an immunologist, researcher and drug developer working in life sciences industry, spanning pharmaceutical, biotechnology, health care and academic institutions.

Emilio joins Ensoma from Boehringer Ingelheim, where he was vice president, head of global immune modulation and head of U.S. cancer immunology. In this role, Emilio led the development of immunotherapies across several therapeutic areas, including oncology, cardiometabolic, respiratory and immunology. Previously, Emilio was an executive director at Merck in the discovery immunology and oncology department, where he led a group of immunologists focused on developing targeted immunomodulatory therapies. Prior to Merck, Emilio held roles at leading biotechnology companies. At Seres Therapeutics, a microbiome company, Emilio was a senior director and led the immunology and inflammatory disease group. At Genocea Biosciences, a T-cell antigen and vaccine company, Emilio supervised preclinical vaccine development and translational immunology. Emilio began his career in academia as a principal investigator and associate professor at the Center for Vaccines and Immunity at Nationwide Children’s Hospital and The Ohio State University.

Emilio received his B.S and Ph.D. from the Universidad de León with a focus on cellular biology and completed post-doctoral trainings at The Trudeau Institute and St. Jude Children’s Research Hospital.